Queralt Salas, MariaMussetti, AlbertoMuñóz, CarmeAlbasanz Puig, AdaiaPatiño, BeatrizJimenez Prat, LauraGudiol González, CarlotaParody, RocíoSureda, Anna2023-01-092023-01-092021-02-082531-1379https://hdl.handle.net/2445/191974Patients undergoing allogeneic stem cell transplantation (alloHCT) require profound immunosuppression is required to preserve graft function and prevent graft-versus host disease (GVHD), resulting in a high risk of infectious complications such as invasive fungal diseases (IFIs). Posaconazole is approved for primary antifungal prophylaxis alloHCT. However, posaconazole is associated with drug-drug interactions which may lead to relevant toxicities limiting it uses in hematological patients. Other triazoles, amphotericine B, and echinocandins can be used in patients at high risk of IFIs. However, there is less evidence supporting the efficacy of these drugs for the prevention of IFIs.4 p.application/pdfengcc-by-nc-nd (c) Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular, 2021https://creativecommons.org/licenses/by-nc-nd/4.0/Cèl·lules mareMedicaments antifúngicsMedicina preventivaStem cellsAntifungal agentsPreventive medicineinfo:eu-repo/semantics/article7111742023-01-09info:eu-repo/semantics/openAccess